OLDSMAR, Fla., March 16, 2022 (GLOBE NEWSWIRE) — Cryo-Cell Worldwide, Inc. (The Nasdaq Inventory Market Image: CCEL) (the “Firm”), the world’s first non-public twine blood financial institution to separate and retailer stem cells in 1992, broadcasts it has entered into a purchase order contract, with the closing topic to customary situations, for a newly constructed, 56,000 sq ft facility situated within the Regional Commerce Heart throughout the Analysis Triangle, NC. We anticipate this facility will increase Cryo-Cell’s cryopreservation and chilly storage enterprise by introducing a brand new service, ExtraVault (www.extravault.com). With over 30 years of expertise in dealing with organic specimens for each analysis and scientific use, Cryo-Cell intends to leverage this experience and supply these biorepository companies to biopharmaceutical corporations and healthcare establishments.
The brand new facility is being constructed to supply state-of-the-art biologics, reagents, vaccine samples and/or whole freezer storage at price efficient costs. A sturdy stock administration system is deliberate to be applied that may enable prospects to view their very own stock by a buyer portal and place distribution orders on-line. The employees at ExtraVault have many years of expertise storing and distributing chilly chain samples nationally and internationally. Because of this, it’s anticipated ExtraVault will present experience, expertise, buyer digital entry and value delicate options to our companions within the biopharma and healthcare industries.
About Cryo-Cell Worldwide, Inc.
Based in 1989, Cryo-Cell Worldwide, Inc. is the world’s first non-public twine blood financial institution. Greater than 500,000 dad and mom from 87 nations have entrusted Cryo-Cell Worldwide with their child’s twine blood and twine tissue stem cells. Along with its non-public financial institution, Cryo-Cell Worldwide has a public banking program in partnership with Duke College. Cryo-Cell’s public financial institution has supplied twine blood for greater than 600 transplantations and operates twine blood donation websites throughout the U.S in outstanding hospitals similar to Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Moreover being AABB accredited as a twine blood facility, Cryo-Cell was additionally the primary U.S. (for personal use solely) twine blood financial institution to obtain FACT accreditation for adhering to essentially the most stringent twine blood high quality requirements set by any internationally acknowledged, impartial accrediting group. Cryo-Cell has the unique rights to PrepaCyte-CB, the business’s most superior twine blood processing know-how.
Cryo-Cell’s mission is to offer the premier twine blood and twine tissue cryopreservation companies, to develop, manufacture and administer mobile therapies to considerably enhance the lives of sufferers worldwide and to supply the very best high quality and most price efficient biostorage options accessible. In February 2021, Cryo-Cell entered right into a license settlement with Duke College that the Firm believes has allowed Cryo-Cell to start its transformation into an autonomous, vertically built-in mobile remedy firm. In March 2022, Cryo-Cell launched ExtraVault to supply its experience in biostorage and distribution to biopharmaceutical corporations and healthcare establishments.
For extra info, please go to www.extravault.com.
Ahead-Trying Statements
This press launch contains “forward-looking statements” throughout the that means of Part 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Part 21E of the Securities Trade Act of 1934, as amended (the “Trade Act”). In some circumstances, you possibly can establish forward-looking statements by terminology similar to “will,” “might,” “ought to,” “might,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “proceed” or the unfavorable of those phrases or different comparable terminology. Usually, the phrases “anticipate,” “imagine,” “proceed,” “anticipate,” “intend,” “estimate,” “undertaking,” “plan” and comparable expressions establish forward-looking statements. Particularly, statements about our expectations, beliefs, plans, goals, assumptions or future occasions or efficiency include forward-looking statements.
We now have based mostly these forward-looking statements on our present expectations, assumptions, estimates and projections. These forward-looking statements contain dangers and uncertainties and replicate solely our present views, expectations and assumptions with respect to future occasions and our future efficiency. If dangers or uncertainties materialize or assumptions show incorrect, precise outcomes or occasions might differ materially from these expressed or implied by such forward-looking statements. Dangers that would trigger precise outcomes to vary from these expressed or implied by the forward-looking statements we make embody, amongst others, dangers associated to: the influence of the COVID-19 pandemic on our gross sales, operations and provide chain, the success of the Firm’s world enlargement initiatives and product diversification, together with its addition of the ExtraVault companies, the Firm’s precise future possession stake in future therapies rising from its collaborative analysis partnerships, the success associated to its IP portfolio, the Firm’s future aggressive place in stem cell innovation, future success of its core enterprise and the aggressive influence of public twine blood banking on the Firm’s enterprise, the success of the Firm’s initiative to increase its core enterprise models to incorporate biopharmaceutical manufacturing and working clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and working clinics, the Firm’s means to reduce future prices to the Firm associated to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Firm’s umbilical twine blood and twine tissue license agreements, along with the related mental property and their means to offer the Firm with royalty charges.
This checklist of dangers and uncertainties, nevertheless, is just a abstract of a few of the most vital elements and isn’t supposed to be exhaustive. Given these dangers and uncertainties, you’re cautioned to not place undue reliance on such forward-looking statements. These dangers and uncertainties might trigger our precise future outcomes to be materially totally different than these expressed in our forward-looking statements. These forward-looking statements are made solely as of the date hereof. Besides as in any other case required by relevant legislation, we don’t undertake and expressly disclaim any obligation to replace any such statements or to publicly announce the outcomes of any revisions to any such statements to replicate future occasions or developments. All subsequent written and oral forward-looking statements attributable to us, or to individuals performing on our behalf, are expressly certified of their entirety by these cautionary statements.
Contact:
Irene Smith
813-749-2102
